Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 205

1.

A molecularly engineered antiviral banana lectin inhibits fusion and is efficacious against influenza virus infection in vivo.

Covés-Datson EM, King SR, Legendre M, Gupta A, Chan SM, Gitlin E, Kulkarni VV, Pantaleón García J, Smee DF, Lipka E, Evans SE, Tarbet EB, Ono A, Markovitz DM.

Proc Natl Acad Sci U S A. 2020 Jan 28;117(4):2122-2132. doi: 10.1073/pnas.1915152117. Epub 2020 Jan 13.

2.

Development of a respiratory disease model for enterovirus D68 in 4-week-old mice for evaluation of antiviral therapies.

Evans WJ, Hurst BL, Peterson CJ, Van Wettere AJ, Day CW, Smee DF, Tarbet EB.

Antiviral Res. 2019 Feb;162:61-70. doi: 10.1016/j.antiviral.2018.11.012. Epub 2018 Dec 3.

3.

Evaluation of antiviral therapies in respiratory and neurological disease models of Enterovirus D68 infection in mice.

Hurst BL, Evans WJ, Smee DF, Van Wettere AJ, Tarbet EB.

Virology. 2019 Jan 2;526:146-154. doi: 10.1016/j.virol.2018.10.014. Epub 2018 Oct 31.

4.

2'-Fluoro-2'-deoxycytidine is a broad-spectrum inhibitor of bunyaviruses in vitro and in phleboviral disease mouse models.

Smee DF, Jung KH, Westover J, Gowen BB.

Antiviral Res. 2018 Dec;160:48-54. doi: 10.1016/j.antiviral.2018.10.013. Epub 2018 Oct 16.

PMID:
30339848
5.

Inhibition of adenovirus serotype 14 infection by octadecyloxyethyl esters of (S)-[(3-hydroxy-2-phosphonomethoxy)propyl]- nucleosides in vitro.

Kumaki Y, Woolcott JD, Roth JP, Mclean TZ, Smee DF, Barnard DL, Valiaeva N, Beadle JR, Hostetler KY.

Antiviral Res. 2018 Oct;158:122-126. doi: 10.1016/j.antiviral.2018.08.004. Epub 2018 Aug 7.

PMID:
30096340
6.

Comparison of three dimensional synergistic analyses of percentage versus logarithmic data in antiviral studies.

Smee DF, Prichard MN.

Antiviral Res. 2017 Sep;145:1-5. doi: 10.1016/j.antiviral.2017.06.022. Epub 2017 Jul 1.

7.

Combinations of L-NG-monomethyl-arginine and oseltamivir against pandemic influenza A virus infections in mice.

Smee DF, Dagley A, Tarbet EB.

Antivir Chem Chemother. 2017 Apr;25(1):11-17. doi: 10.1177/2040206617691885. Epub 2017 Mar 21.

8.

Isolation and identification of compounds from Kalanchoe pinnata having human alphaherpesvirus and vaccinia virus antiviral activity.

Cryer M, Lane K, Greer M, Cates R, Burt S, Andrus M, Zou J, Rogers P, Hansen MD, Burgado J, Panayampalli SS, Day CW, Smee DF, Johnson BF.

Pharm Biol. 2017 Dec;55(1):1586-1591. doi: 10.1080/13880209.2017.1310907. Erratum in: Pharm Biol. 2017 Dec;55(1):2297.

9.

Evaluation of cell viability dyes in antiviral assays with RNA viruses that exhibit different cytopathogenic properties.

Smee DF, Hurst BL, Evans WJ, Clyde N, Wright S, Peterson C, Jung KH, Day CW.

J Virol Methods. 2017 Aug;246:51-57. doi: 10.1016/j.jviromet.2017.03.012. Epub 2017 Mar 27.

10.

An M2-V27A channel blocker demonstrates potent in vitro and in vivo antiviral activities against amantadine-sensitive and -resistant influenza A viruses.

Hu Y, Musharrafieh R, Ma C, Zhang J, Smee DF, DeGrado WF, Wang J.

Antiviral Res. 2017 Apr;140:45-54. doi: 10.1016/j.antiviral.2017.01.006. Epub 2017 Jan 10.

11.

Activities of JNJ63623872 and oseltamivir against influenza A H1N1pdm and H3N2 virus infections in mice.

Smee DF, Barnard DL, Jones SM.

Antiviral Res. 2016 Dec;136:45-50. doi: 10.1016/j.antiviral.2016.10.009. Epub 2016 Oct 19.

PMID:
27771390
12.

The Iminosugar UV-4 is a Broad Inhibitor of Influenza A and B Viruses ex Vivo and in Mice.

Warfield KL, Barnard DL, Enterlein SG, Smee DF, Khaliq M, Sampath A, Callahan MV, Ramstedt U, Day CW.

Viruses. 2016 Mar 7;8(3):71. doi: 10.3390/v8030071.

13.

Susceptibilities of enterovirus D68, enterovirus 71, and rhinovirus 87 strains to various antiviral compounds.

Smee DF, Evans WJ, Nicolaou KC, Tarbet EB, Day CW.

Antiviral Res. 2016 Jul;131:61-5. doi: 10.1016/j.antiviral.2016.04.003. Epub 2016 Apr 7.

14.

A Computationally Designed Hemagglutinin Stem-Binding Protein Provides In Vivo Protection from Influenza Independent of a Host Immune Response.

Koday MT, Nelson J, Chevalier A, Koday M, Kalinoski H, Stewart L, Carter L, Nieusma T, Lee PS, Ward AB, Wilson IA, Dagley A, Smee DF, Baker D, Fuller DH.

PLoS Pathog. 2016 Feb 4;12(2):e1005409. doi: 10.1371/journal.ppat.1005409. eCollection 2016 Feb.

15.

The Synthetic Antiviral Drug Arbidol Inhibits Globally Prevalent Pathogenic Viruses.

Pécheur EI, Borisevich V, Halfmann P, Morrey JD, Smee DF, Prichard M, Mire CE, Kawaoka Y, Geisbert TW, Polyak SJ.

J Virol. 2016 Jan 6;90(6):3086-92. doi: 10.1128/JVI.02077-15.

16.

Low-dose ribavirin potentiates the antiviral activity of favipiravir against hemorrhagic fever viruses.

Westover JB, Sefing EJ, Bailey KW, Van Wettere AJ, Jung KH, Dagley A, Wandersee L, Downs B, Smee DF, Furuta Y, Bray M, Gowen BB.

Antiviral Res. 2016 Feb;126:62-8. doi: 10.1016/j.antiviral.2015.12.006. Epub 2015 Dec 19.

17.

Engineering a therapeutic lectin by uncoupling mitogenicity from antiviral activity.

Swanson MD, Boudreaux DM, Salmon L, Chugh J, Winter HC, Meagher JL, André S, Murphy PV, Oscarson S, Roy R, King S, Kaplan MH, Goldstein IJ, Tarbet EB, Hurst BL, Smee DF, de la Fuente C, Hoffmann HH, Xue Y, Rice CM, Schols D, Garcia JV, Stuckey JA, Gabius HJ, Al-Hashimi HM, Markovitz DM.

Cell. 2015 Oct 22;163(3):746-58. doi: 10.1016/j.cell.2015.09.056. Epub 2015 Oct 22.

18.

Alterations in favipiravir (T-705) pharmacokinetics and biodistribution in a hamster model of viral hemorrhagic fever.

Gowen BB, Sefing EJ, Westover JB, Smee DF, Hagloch J, Furuta Y, Hall JO.

Antiviral Res. 2015 Sep;121:132-7. doi: 10.1016/j.antiviral.2015.07.003. Epub 2015 Jul 14.

19.

Enhanced efficacy of cidofovir combined with vaccinia immune globulin in treating progressive cutaneous vaccinia virus infections in immunosuppressed hairless mice.

Smee DF, Dagley A, Downs B, Hagloch J, Tarbet EB.

Antimicrob Agents Chemother. 2015 Jan;59(1):520-6. doi: 10.1128/AAC.04289-14. Epub 2014 Nov 10.

20.

BCX4430, a novel nucleoside analog, effectively treats yellow fever in a Hamster model.

Julander JG, Bantia S, Taubenheim BR, Minning DM, Kotian P, Morrey JD, Smee DF, Sheridan WP, Babu YS.

Antimicrob Agents Chemother. 2014 Nov;58(11):6607-14. doi: 10.1128/AAC.03368-14. Epub 2014 Aug 25.

21.

Influenza Virus H1N1 inhibition by serine protease inhibitor (serpin) antithrombin III.

Smee DF, Hurst BL, Day CW, Geiben-Lynn R.

Int Trends Immun. 2014 Apr 1;2(2):83-86.

22.

The use of plethysmography in determining the severity of lung pathology in a mouse model of minimally lethal influenza virus infection.

Julander JG, Kesler K, Van Wettere AJ, Morrey JD, Smee DF.

Antiviral Res. 2014 Aug;108:10-3. doi: 10.1016/j.antiviral.2014.05.002. Epub 2014 May 14.

PMID:
24837607
23.

A zanamivir dimer with prophylactic and enhanced therapeutic activity against influenza viruses.

Tarbet EB, Hamilton S, Vollmer AH, Luttick A, Ng WC, Pryor M, Hurst BL, Crawford S, Smee DF, Tucker SP.

J Antimicrob Chemother. 2014 Aug;69(8):2164-74. doi: 10.1093/jac/dku127. Epub 2014 Apr 28.

24.
25.
26.

In vitro activity of favipiravir and neuraminidase inhibitor combinations against oseltamivir-sensitive and oseltamivir-resistant pandemic influenza A (H1N1) virus.

Tarbet EB, Vollmer AH, Hurst BL, Barnard DL, Furuta Y, Smee DF.

Arch Virol. 2014 Jun;159(6):1279-91. doi: 10.1007/s00705-013-1922-1. Epub 2013 Dec 6.

PMID:
24311151
27.

Innate immune protection against infectious diseases by pulmonary administration of a phospholipid-conjugated TLR7 ligand.

Wu CC, Crain B, Yao S, Sabet M, Lao FS, Tawatao RI, Chan M, Smee DF, Julander JG, Cottam HB, Guiney DG, Corr M, Carson DA, Hayashi T.

J Innate Immun. 2014;6(3):315-24. doi: 10.1159/000355217. Epub 2013 Nov 1.

28.

Favipiravir (T-705), a novel viral RNA polymerase inhibitor.

Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL.

Antiviral Res. 2013 Nov;100(2):446-54. doi: 10.1016/j.antiviral.2013.09.015. Epub 2013 Sep 29. Review.

29.
30.

Methods for evaluation of antiviral efficacy against influenza virus infections in animal models.

Smee DF, Barnard DL.

Methods Mol Biol. 2013;1030:407-25. doi: 10.1007/978-1-62703-484-5_31.

PMID:
23821285
31.

Synthesis and biological activity evaluation of 5-pyrazoline substituted 4-thiazolidinones.

Havrylyuk D, Zimenkovsky B, Vasylenko O, Day CW, Smee DF, Grellier P, Lesyk R.

Eur J Med Chem. 2013 Aug;66:228-37. doi: 10.1016/j.ejmech.2013.05.044. Epub 2013 Jun 6.

PMID:
23811085
32.

Antivirally active ribavirin analogues--4,5-disubstituted 1,2,3-triazole nucleosides: biological evaluation against certain respiratory viruses and computational modelling.

Krajczyk A, Kulinska K, Kulinski T, Hurst BL, Day CW, Smee DF, Ostrowski T, Januszczyk P, Zeidler J.

Antivir Chem Chemother. 2014 Jan 29;23(4):161-71. doi: 10.3851/IMP2564.

PMID:
23538746
33.

Activity of a phenolic dibenzylsulfide against New World arenavirus infections.

Gowen BB, Jung KH, Sefing EJ, Wong MH, Westover JB, Smee DF.

Antivir Chem Chemother. 2014 Jan 29;23(4):151-9. doi: 10.3851/IMP2532.

34.

Exacerbation of influenza virus infections in mice by intranasal treatments and implications for evaluation of antiviral drugs.

Smee DF, von Itzstein M, Bhatt B, Tarbet EB.

Antimicrob Agents Chemother. 2012 Dec;56(12):6328-33. doi: 10.1128/AAC.01664-12. Epub 2012 Oct 1.

35.

Synthesis and biological evaluation of epidithio-, epitetrathio-, and bis-(methylthio)diketopiperazines: synthetic methodology, enantioselective total synthesis of epicoccin G, 8,8'-epi-ent-rostratin B, gliotoxin, gliotoxin G, emethallicin E, and haematocin and discovery of new antiviral and antimalarial agents.

Nicolaou KC, Lu M, Totokotsopoulos S, Heretsch P, Giguère D, Sun YP, Sarlah D, Nguyen TH, Wolf IC, Smee DF, Day CW, Bopp S, Winzeler EA.

J Am Chem Soc. 2012 Oct 17;134(41):17320-32. doi: 10.1021/ja308429f. Epub 2012 Oct 4.

36.

Treatment of oseltamivir-resistant influenza A (H1N1) virus infections in mice with antiviral agents.

Smee DF, Julander JG, Tarbet EB, Gross M, Nguyen J.

Antiviral Res. 2012 Oct;96(1):13-20. doi: 10.1016/j.antiviral.2012.07.002. Epub 2012 Jul 15.

37.

D282, a non-nucleoside inhibitor of influenza virus infection that interferes with de novo pyrimidine biosynthesis.

Smee DF, Hurst BL, Day CW.

Antivir Chem Chemother. 2012 Aug 21;22(6):263-72. doi: 10.3851/IMP2105.

PMID:
22516927
38.

Combinations of favipiravir and peramivir for the treatment of pandemic influenza A/California/04/2009 (H1N1) virus infections in mice.

Tarbet EB, Maekawa M, Furuta Y, Babu YS, Morrey JD, Smee DF.

Antiviral Res. 2012 Apr;94(1):103-10. doi: 10.1016/j.antiviral.2012.03.001. Epub 2012 Mar 10.

39.

Inhibition of influenza A virus replication by antagonism of a PI3K-AKT-mTOR pathway member identified by gene-trap insertional mutagenesis.

Murray JL, McDonald NJ, Sheng J, Shaw MW, Hodge TW, Rubin DH, O'Brien WA, Smee DF.

Antivir Chem Chemother. 2012 May 14;22(5):205-15. doi: 10.3851/IMP2080.

PMID:
22374988
40.

Efficacy of combined therapy with amantadine, oseltamivir, and ribavirin in vivo against susceptible and amantadine-resistant influenza A viruses.

Nguyen JT, Smee DF, Barnard DL, Julander JG, Gross M, de Jong MD, Went GT.

PLoS One. 2012;7(1):e31006. doi: 10.1371/journal.pone.0031006. Epub 2012 Jan 23.

41.

Effective oral favipiravir (T-705) therapy initiated after the onset of clinical disease in a model of arenavirus hemorrhagic Fever.

Mendenhall M, Russell A, Smee DF, Hall JO, Skirpstunas R, Furuta Y, Gowen BB.

PLoS Negl Trop Dis. 2011 Oct;5(10):e1342. doi: 10.1371/journal.pntd.0001342. Epub 2011 Oct 11.

42.

Therapy and long-term prophylaxis of vaccinia virus respiratory infections in mice with an adenovirus-vectored interferon alpha (mDEF201).

Smee DF, Wong MH, Russell A, Ennis J, Turner JD.

PLoS One. 2011;6(10):e26330. doi: 10.1371/journal.pone.0026330. Epub 2011 Oct 13.

43.

In vitro and in vivo efficacy of fluorodeoxycytidine analogs against highly pathogenic avian influenza H5N1, seasonal, and pandemic H1N1 virus infections.

Kumaki Y, Day CW, Smee DF, Morrey JD, Barnard DL.

Antiviral Res. 2011 Nov;92(2):329-40. doi: 10.1016/j.antiviral.2011.09.001. Epub 2011 Sep 8.

44.

Use of plethysmography in assessing the efficacy of antivirals in a mouse model of pandemic influenza A virus.

Julander JG, Hagloch J, Latimer S, Motter N, Dagley A, Barnard DL, Smee DF, Morrey JD.

Antiviral Res. 2011 Nov;92(2):228-36. doi: 10.1016/j.antiviral.2011.08.011. Epub 2011 Aug 17.

PMID:
21867731
45.

Effects of TheraMax on influenza virus infections in cell culture and in mice.

Smee DF, Hurst BL, Wong MH.

Antivir Chem Chemother. 2011 Jul 4;21(6):231-7. doi: 10.3851/IMP1744.

PMID:
21730370
46.

Topical treatment of cutaneous vaccinia virus infections in immunosuppressed hairless mice with selected antiviral substances.

Smee DF, Bailey KW, Wong MH, Tarbet EB.

Antivir Chem Chemother. 2011 May 12;21(5):201-8. doi: 10.3851/IMP1734.

PMID:
21566266
47.

Maporal virus as a surrogate for pathogenic New World hantaviruses and its inhibition by favipiravir.

Buys KK, Jung KH, Smee DF, Furuta Y, Gowen BB.

Antivir Chem Chemother. 2011 May 12;21(5):193-200. doi: 10.3851/IMP1729.

48.

Evaluation of imiquimod for topical treatment of vaccinia virus cutaneous infections in immunosuppressed hairless mice.

Tarbet EB, Larson D, Anderson BJ, Bailey KW, Wong MH, Smee DF.

Antiviral Res. 2011 Jun;90(3):126-33. doi: 10.1016/j.antiviral.2011.03.181. Epub 2011 Mar 23.

49.

Inhibition of severe acute respiratory syndrome coronavirus replication in a lethal SARS-CoV BALB/c mouse model by stinging nettle lectin, Urtica dioica agglutinin.

Kumaki Y, Wandersee MK, Smith AJ, Zhou Y, Simmons G, Nelson NM, Bailey KW, Vest ZG, Li JK, Chan PK, Smee DF, Barnard DL.

Antiviral Res. 2011 Apr;90(1):22-32. doi: 10.1016/j.antiviral.2011.02.003. Epub 2011 Feb 19.

50.

T-705 (favipiravir) inhibition of arenavirus replication in cell culture.

Mendenhall M, Russell A, Juelich T, Messina EL, Smee DF, Freiberg AN, Holbrook MR, Furuta Y, de la Torre JC, Nunberg JH, Gowen BB.

Antimicrob Agents Chemother. 2011 Feb;55(2):782-7. doi: 10.1128/AAC.01219-10. Epub 2010 Nov 29.

Supplemental Content

Support Center